Melanoma Clinical Trials in Arizona

Showing 141-160 of 238 trials

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

NCT03265080

This is a Phase 1, open-label, multicenter study of ADXS-NEO administered alone and in combination with pembrolizumab in participants with select advanced or metastatic solid tumors. This study will be performed in 2 phases, a safety phase (Part A and Part B) and an efficacy phase (Part C).

Colon Cancer MetastaticHead and Neck Cancer MetastaticMetastatic Non-Small Cell Lung Cancer+2 more

Advaxis, Inc.13 participantsStarted Mar 2018

Scottsdale, Arizona, United States • Los Angeles, California, United States • New Orleans, Louisiana, United States +2 more locations

TERMINATED31 miles

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

NCT05061940

The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient suitability for a Repertoire Immune Medicines Treatment Protocol.

Head and Neck CancerMelanomaHPV-Related Malignancy+5 more

Repertoire Immune Medicines22 participantsStarted May 2021

Scottsdale, Arizona, United States • Ann Arbor, Michigan, United States • Nashville, Tennessee, United States

COMPLETEDPhase 131 miles

A Study of PLX2853 in Advanced Malignancies.

NCT03297424

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.

Small Cell Lung CancerUveal MelanomaOvarian Clear Cell Carcinoma+5 more

Opna Bio LLC49 participantsStarted Sep 2017

Scottsdale, Arizona, United States • Miami, Florida, United States • New York, New York, United States +2 more locations

PreviousPage 8 of 12Next

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

A Study of PLX2853 in Advanced Malignancies.

Melanoma Trials in Other Cities

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

Safety Study of MGA271 in Refractory Cancer

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Other Conditions in Arizona